TABLE 2.
The characteristics of the chemotherapy treatment in advanced angiosarcoma cohort
| Frequency (%) | P‐value | |||
|---|---|---|---|---|
| Total | LA/UR/Mets at diagnosis | Mets at FU | ||
| N = 143 | n = 103 (72%) | n = 40 (28%) | ||
| Lines of chemotherapy | .001 # | |||
| Median (IQR) | 1 (1, 2) | 2 (1, 2) | 1 (1, 1) | |
| Range | 1‐5 | 1‐5 | 1‐3 | |
| Lines of chemotherapy | .02 ^ | |||
| 1 | 80 (55.9) | 49 (47.6) | 31 (77.5) | |
| 2 | 35 (24.5) | 30 (29.1) | 5 (12.5) | |
| 3 | 17 (11.9) | 13 (12.6) | 4 (10.0) | |
| 4 | 6 (4.2) | 6 (5.8) | 0 (0.0) | |
| 5 | 5 (3.5) | 5 (4.9) | 0 (0.0) | |
| Lines of chemotherapy | .005 | |||
| 1 | 80 (55.9) | 49 (47.6) | 31 (77.5) | |
| 2 | 35 (24.5) | 30 (29.1) | 5 (12.5) | |
| ≥3 | 28 (19.6) | 24 (23.3) | 4 (10.0) | |
| First‐line chemotherapy agent(s) | .3 | |||
| Single | 114 (79.7) | 80 (77.7) | 34 (85.0) | |
| Combination | 29 (20.3) | 23 (22.3) | 6 (15.0) | |
| First‐line chemotherapy agent(s) | .01 ^ (.007) | |||
| Liposomal doxorubicin | 28 (19.6) | 16 (15.5) | 12 (30.0) | |
| Paclitaxel | 68 (47.6) | 57 (55.3) | 11 (27.5) | |
| Others | 45 (31.5) | 28 (27.2) | 17 (42.5) | |
| Unknown | 2 (1.4) | 2 (1.9) | 0 (0.0) | |
| First‐line chemotherapy agent(s) | <.001 ^ (<.001 ^ ) | |||
| Liposomal doxorubicin | 28 (19.6) | 16 (15.5) | 12 (30.0) | |
| Paclitaxel | 68 (47.6) | 57 (55.3) | 11 (27.5) | |
| Others‐single | 16 (11.2) | 5 (4.9) | 11 (27.5) | |
| Others‐combination | 29 (20.3) | 23 (22.3) | 6 (15.0) | |
| Unknown | 2 (1.4) | 2 (1.9) | 0 (0.0) | |
| First‐line chemo cycles | .5 ^ (.4) | |||
| <6 | 90 (62.9) | 62 (60.2) | 28 (70.0) | |
| ≥6 | 45 (31.5) | 34 (33.0) | 11 (27.5) | |
| Unknown | 8 (5.6) | 7 (6.8) | 1 (2.5) | |
P‐value estimated using chi‐squared test unless otherwise stated.
P‐value within parenthesis excludes the category "Unknown."
#
P‐value estimated using Mann‐Whitney U test.
^
P‐value estimated using Fisher's exact test.